SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced that REPEL-CV, the company’s bioresorbable adhesion barrier film for the reduction of adhesions following cardiac surgery, has received approval from the Ministry of Health of the Russian Federation for use in all patients who undergo open heart surgery. REPEL-CV will be marketed throughout Russia by Cardiomedics, Ltd.
Home » SyntheMed Receives Russian Regulatory Approval For REPEL-CV(TM)